Northwest Biotherapeutics reported $7.07M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
AstraZeneca USD 5.06B 455M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Celldex Therapeutics USD 11.45M 3.61M Mar/2026
Eisai JPY 119.54B 7.82B Mar/2026
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
Merck USD 2.67B 180M Mar/2026
Northwest Biotherapeutics USD 7.07M 1.06M Sep/2025
Pfizer USD 2.92B 1.16B Mar/2026
Plus Therapeutics USD 3.49M 559K Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025